News & Events

Press Releases

March 22, 2023

Kyverna Announces Expansion of Sponsored Research Agreement with Prof. Dr. Schett at Friedrich-Alexander-Universität Erlangen-Nürnberg

January 6, 2023

Kyverna Therapeutics Submits CTA for Phase 1/2 Clinical Study of KYV-101 in Germany

December 13, 2022

Kyverna Congratulates Scientific Advisory Board Member Georg Schett, M.D., on Receiving Gottfried Wilhelm Leibniz Prize

November 11, 2022

Kyverna Therapeutics Announces FDA Clearance of IND for KYV-101, a Novel Fully Human CD19 CAR T-Cell Therapy to Treat Lupus Nephritis

October 18, 2022

Kyverna Therapeutics Submits IND for Novel CAR T-Cell Therapy to Treat Lupus Nephritis

October 13, 2022

Kyverna Therapeutics Names Peter Maag, Ph.D., as Chief Executive Officer

August 23, 2022

Kyverna Therapeutics Names Georg Schett, M.D., and Peter A. Merkel, M.D., MPH, to Scientific Advisory Board

August 23, 2022

Kyverna Therapeutics Names Cell Therapy Expert Tom Van Blarcom, Ph.D., as Senior Vice President, Head of Research

January 26, 2022

Kyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures

January 5, 2022

Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases

Media Inquiries

To learn more about Kyverna’s work developing cell therapies for inflammatory and autoimmune disease, please reach out to us at:

media@kyvernatx.com